top of page
Private Equity Fund
Pre-Deal Critical Assessment
A European Private Equity firm engaged us to perform a critical assessment of their valuation model and assumptions prior to completing a sizeable investment into a Neurology Start-up
​
With time of the essence, we provided expert advice on revenue and OPEX assumptions within tight timelines to allow our client to successfully close the investment
Private Investor
Company Valuation
A private investor and founder of an early-stage biotech engaged us to conduct a valuation of his business, which included two assets in pre-clinical and phase I
​
We provided a comprehensive analysis and financial model to identify key value inflection points of the individual indications as well as the firm as a whole
Early-Stage Biotech
Value Creation Planning &
Executive Management
The founder of an early-stage biopharma start-up retained us as the lead executive business consultant, responsible for designing and operationalising value creation plans as well as preparing the business for fund-raising
Late-Stage Biotech
Product Strategy & Executive Advisory
Old Street Strategy was retained as an executive advisor by a late-stage, PE-funded biotech start-up to support the founding CEO with product strategy, market access and go-to-market planning as well as recruitment of executive leadership positions
Digital Health Start-up
Monetisation Strategy
The founder of a digital health start-up commissioned us to identify potential monetisation options for their mental health digital therapeutic app and subsequently validate a revenue development strategy through primary research with a variety of private sector, healthcare and charity stakeholders
The recommendations were a foundational requirement supporting the subsequent fund-raising efforts by the firm
Late-Stage Biopharma
Market Expansion Strategy
A late-stage, listed biotech commissioned us to conduct an international market opportunity assessment and develop a geographic expansion strategy for their launch asset
​
We led a cross-functional client team as well as external intelligence suppliers to develop a comprehensive recommendation based on NPV and strategic analyses
Late-Stage Biopharma
Lifecycle Strategy & Indication Expansion
We were commissioned by a late-stage, PE-funded start-up to assess potential lifecycle opportunities and develop a recommendation, utilising primary market research, market valuations and strategic opportunity assessments
​
bottom of page